Medical optimization of lumbar fusion in the osteoporotic patient

Matthew T. Morris, Sandip P. Tarpada, Vafa Tabatabaie, Woojin Cho

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose: In patients undergoing lumbar fusion, osteoporosis has been shown to lead to poorer outcomes and greater incidence of fusion-related complications. Given the undesirable effect of osteoporosis on lumbar fusion surgery, a number of medications have been proposed for use in the peri- and postoperative period to mitigate risks and enhance outcomes. The purpose of this review was to summarize and synthesize the current literature regarding medical management of osteoporosis in the context of lumbar fusion surgery. Methods: A literature search of PubMed, Embase, and Web of Science was conducted in October 2016, using permutations of various search terms related to osteoporosis, medications, and lumbar fusion. Results: Teriparatide injections may lead to faster, more successful fusion, and may reduce fusion-related complications. Bisphosphonate therapy likely does not hinder fusion outcomes and may be useful in reducing certain complications of fusion in osteoporotic patients. Calcitonin and selective estrogen receptor modulator therapy show mixed results, but more research is necessary to make a recommendation. Vitamin D deficiency is associated with poor fusion outcomes, but evidence for supplementation in patients with normal serum levels is weak. Conclusions: Overall, the current body of research appears to support the use of teriparatide therapy to enhance lumbar fusion outcomes in the osteoporotic patient, although the extent of research on this topic is limited. Additionally, very little evidence exists to cease any of the mentioned osteoporosis treatments prior to lumbar fusion.

Original languageEnglish (US)
Article number26
JournalArchives of Osteoporosis
Volume13
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Osteoporosis
Teriparatide
Research
Selective Estrogen Receptor Modulators
Perioperative Period
Vitamin D Deficiency
Diphosphonates
Calcitonin
Therapeutics
Postoperative Period
PubMed
Injections
Incidence
Serum

Keywords

  • Bisphosphonates
  • Bone mineral density
  • Calcitonin
  • Fusion rate
  • Lumbar fusion
  • Lumbar spine
  • Medical treatment
  • Osteoporosis
  • Selective estrogen receptor modulators
  • Teriparatide
  • Vitamin D

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Medical optimization of lumbar fusion in the osteoporotic patient. / Morris, Matthew T.; Tarpada, Sandip P.; Tabatabaie, Vafa; Cho, Woojin.

In: Archives of Osteoporosis, Vol. 13, No. 1, 26, 01.12.2018.

Research output: Contribution to journalReview article

@article{0314cbb7fbed43fca7ee94454918e3db,
title = "Medical optimization of lumbar fusion in the osteoporotic patient",
abstract = "Purpose: In patients undergoing lumbar fusion, osteoporosis has been shown to lead to poorer outcomes and greater incidence of fusion-related complications. Given the undesirable effect of osteoporosis on lumbar fusion surgery, a number of medications have been proposed for use in the peri- and postoperative period to mitigate risks and enhance outcomes. The purpose of this review was to summarize and synthesize the current literature regarding medical management of osteoporosis in the context of lumbar fusion surgery. Methods: A literature search of PubMed, Embase, and Web of Science was conducted in October 2016, using permutations of various search terms related to osteoporosis, medications, and lumbar fusion. Results: Teriparatide injections may lead to faster, more successful fusion, and may reduce fusion-related complications. Bisphosphonate therapy likely does not hinder fusion outcomes and may be useful in reducing certain complications of fusion in osteoporotic patients. Calcitonin and selective estrogen receptor modulator therapy show mixed results, but more research is necessary to make a recommendation. Vitamin D deficiency is associated with poor fusion outcomes, but evidence for supplementation in patients with normal serum levels is weak. Conclusions: Overall, the current body of research appears to support the use of teriparatide therapy to enhance lumbar fusion outcomes in the osteoporotic patient, although the extent of research on this topic is limited. Additionally, very little evidence exists to cease any of the mentioned osteoporosis treatments prior to lumbar fusion.",
keywords = "Bisphosphonates, Bone mineral density, Calcitonin, Fusion rate, Lumbar fusion, Lumbar spine, Medical treatment, Osteoporosis, Selective estrogen receptor modulators, Teriparatide, Vitamin D",
author = "Morris, {Matthew T.} and Tarpada, {Sandip P.} and Vafa Tabatabaie and Woojin Cho",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s11657-018-0427-7",
language = "English (US)",
volume = "13",
journal = "Archives of Osteoporosis",
issn = "1862-3522",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Medical optimization of lumbar fusion in the osteoporotic patient

AU - Morris, Matthew T.

AU - Tarpada, Sandip P.

AU - Tabatabaie, Vafa

AU - Cho, Woojin

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Purpose: In patients undergoing lumbar fusion, osteoporosis has been shown to lead to poorer outcomes and greater incidence of fusion-related complications. Given the undesirable effect of osteoporosis on lumbar fusion surgery, a number of medications have been proposed for use in the peri- and postoperative period to mitigate risks and enhance outcomes. The purpose of this review was to summarize and synthesize the current literature regarding medical management of osteoporosis in the context of lumbar fusion surgery. Methods: A literature search of PubMed, Embase, and Web of Science was conducted in October 2016, using permutations of various search terms related to osteoporosis, medications, and lumbar fusion. Results: Teriparatide injections may lead to faster, more successful fusion, and may reduce fusion-related complications. Bisphosphonate therapy likely does not hinder fusion outcomes and may be useful in reducing certain complications of fusion in osteoporotic patients. Calcitonin and selective estrogen receptor modulator therapy show mixed results, but more research is necessary to make a recommendation. Vitamin D deficiency is associated with poor fusion outcomes, but evidence for supplementation in patients with normal serum levels is weak. Conclusions: Overall, the current body of research appears to support the use of teriparatide therapy to enhance lumbar fusion outcomes in the osteoporotic patient, although the extent of research on this topic is limited. Additionally, very little evidence exists to cease any of the mentioned osteoporosis treatments prior to lumbar fusion.

AB - Purpose: In patients undergoing lumbar fusion, osteoporosis has been shown to lead to poorer outcomes and greater incidence of fusion-related complications. Given the undesirable effect of osteoporosis on lumbar fusion surgery, a number of medications have been proposed for use in the peri- and postoperative period to mitigate risks and enhance outcomes. The purpose of this review was to summarize and synthesize the current literature regarding medical management of osteoporosis in the context of lumbar fusion surgery. Methods: A literature search of PubMed, Embase, and Web of Science was conducted in October 2016, using permutations of various search terms related to osteoporosis, medications, and lumbar fusion. Results: Teriparatide injections may lead to faster, more successful fusion, and may reduce fusion-related complications. Bisphosphonate therapy likely does not hinder fusion outcomes and may be useful in reducing certain complications of fusion in osteoporotic patients. Calcitonin and selective estrogen receptor modulator therapy show mixed results, but more research is necessary to make a recommendation. Vitamin D deficiency is associated with poor fusion outcomes, but evidence for supplementation in patients with normal serum levels is weak. Conclusions: Overall, the current body of research appears to support the use of teriparatide therapy to enhance lumbar fusion outcomes in the osteoporotic patient, although the extent of research on this topic is limited. Additionally, very little evidence exists to cease any of the mentioned osteoporosis treatments prior to lumbar fusion.

KW - Bisphosphonates

KW - Bone mineral density

KW - Calcitonin

KW - Fusion rate

KW - Lumbar fusion

KW - Lumbar spine

KW - Medical treatment

KW - Osteoporosis

KW - Selective estrogen receptor modulators

KW - Teriparatide

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=85044256152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044256152&partnerID=8YFLogxK

U2 - 10.1007/s11657-018-0427-7

DO - 10.1007/s11657-018-0427-7

M3 - Review article

VL - 13

JO - Archives of Osteoporosis

JF - Archives of Osteoporosis

SN - 1862-3522

IS - 1

M1 - 26

ER -